Uncategorized
Nepafenac reduces risk for macular edema after cataract surgery in select patients
Two studies have shown the benefits of topical nepafenac 0.3% in reducing the risk for macular edema and pseudophakic cystoid macular edema in certain patients.For patients who exhibit risk factors for pseudophakic cystoid macular edema (PCME), the adjunctive use of nepafenac with topical steroids can significantly reduce their chances of developing the condition after phacoemulsification, Sean J. McCafferty, MD, told Ocular Surgery News.